Is GlucoTrack Stock a Good Investment?

GlucoTrack Investment Advice

GCTK

To provide specific investment advice or recommendations on GlucoTrack stock, we recommend investors consider the following general factors when evaluating GlucoTrack. This will help you to make an informed decision on whether to include GlucoTrack in one of your diversified portfolios:

Examine GlucoTrack's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research GlucoTrack's leadership team and their track record. Good management can help GlucoTrack navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact GlucoTrack's business and its evolving consumer preferences.
Compare GlucoTrack's performance and market position to its competitors. Analyze how GlucoTrack is positioned in terms of product offerings, innovation, and market share.
Check if GlucoTrack pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about GlucoTrack's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in GlucoTrack stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GlucoTrack is a good investment.

Sell

Buy

Strong Sell

We provide advice to complement the regular expert consensus on GlucoTrack. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure GlucoTrack is not overpriced, please check out all GlucoTrack fundamentals, including its total debt, as well as the relationship between the short ratio and total asset . Please also validate GlucoTrack number of shares shorted to confirm your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Market Performance	Very Weak	Details
Volatility	Extremely Dangerous	Details
Hype Condition	Over hyped	Details
Current Valuation	Fairly Valued	Details
Odds Of Distress	Very High	Details
Economic Sensitivity	Hyperactively responds to market trends	Details
Investor Sentiment	Impartial	Details
Analyst Consensus	Not Available	Details
Financial Strenth (F Score)	Frail	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unlikely Manipulator	Details

Examine GlucoTrack Stock

Researching GlucoTrack's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 37.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.66. GlucoTrack had not issued any dividends in recent years. The entity had 1:5 split on the 20th of May 2024.

To determine if GlucoTrack is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlucoTrack's research are outlined below:

	GlucoTrack generated a negative expected return over the last 90 days
	GlucoTrack has high historical volatility and very poor performance
	GlucoTrack may become a speculative penny stock
	GlucoTrack has a very high chance of going through financial distress in the upcoming years
	Net Loss for the year was (7.1 M) with loss before overhead, payroll, taxes, and interest of (20 K).
	GlucoTrack currently holds about 3.85 M in cash with (6.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25.
	GlucoTrack has a frail financial position based on the latest SEC disclosures
	Roughly 37.0% of the company shares are held by company insiders
	Latest headline from thelincolnianonline.com: GlucoTrack, Inc. Short Interest Down 12.0 percent in October

GlucoTrack uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlucoTrack. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlucoTrack's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	29th of March 2024 Upcoming Quarterly Report	View
	31st of December 2023 Next Fiscal Quarter End	View

Know GlucoTrack's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as GlucoTrack is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlucoTrack backward and forwards among themselves. GlucoTrack's institutional investor refers to the entity that pools money to purchase GlucoTrack's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Alerus Financial Na	2024-06-30	13.9 K
Cetera Investment Advisers	2024-06-30	10 K
Ubs Group Ag	2024-06-30	6.1 K
Renaissance Technologies Corp	2024-06-30	0.0
Susquehanna International Group, Llp	2024-06-30	0.0
Sabby Management Llc	2024-06-30	0.0
Accurate Wealth Management, Llc	2024-06-30	0.0
Virtue Capital Management, Llc	2024-06-30	0.0
Citadel Advisors Llc	2024-06-30	0.0

Note, although GlucoTrack's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

GlucoTrack's market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.14 M.

Market Cap

304.43 Million

GlucoTrack's profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	(1.45)	(1.52)
Return On Capital Employed	(2.09)	(1.99)
Return On Assets	(1.45)	(1.52)
Return On Equity	(2.22)	(2.11)

Determining GlucoTrack's profitability involves analyzing its financial statements and using various financial metrics to determine if GlucoTrack is a good buy. For example, gross profit margin measures GlucoTrack's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlucoTrack's profitability and make more informed investment decisions.

Evaluate GlucoTrack's management efficiency

GlucoTrack has return on total asset (ROA) of (1.575) % which means that it has lost $1.575 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.4113) %, meaning that it created substantial loss on money invested by shareholders. GlucoTrack's management efficiency ratios could be used to measure how well GlucoTrack manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -1.52. Return On Capital Employed is expected to rise to -1.99 this year. At this time, GlucoTrack's Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 69.9 K this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 3.8 M.

	Last Reported	Projected for Next Year
Book Value Per Share	0.86	0.91
Tangible Book Value Per Share	0.86	0.91
Enterprise Value Over EBITDA	(0.08)	(0.08)
Price Book Value Ratio	1.52	1.59
Enterprise Value Multiple	(0.08)	(0.08)
Price Fair Value	1.52	1.59
Enterprise Value	284.7 M	298.9 M

Understanding the operational decisions made by GlucoTrack management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.

Beta

0.161

Basic technical analysis of GlucoTrack Stock

As of the 13th of November 2024, GlucoTrack retains the Market Risk Adjusted Performance of 0.2163, risk adjusted performance of 0.0881, and Downside Deviation of 8.79. GlucoTrack technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

GlucoTrack's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlucoTrack insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlucoTrack's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GlucoTrack insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Darivoff Philip over a month ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack at 5.8 subject to Rule 16b-3
		Paul Goode over three months ago Acquisition by Paul Goode of 42000 shares of GlucoTrack at 4.95 subject to Rule 16b-3
		Darivoff Philip over six months ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack at 5.8 subject to Rule 16b-3
		Darivoff Philip over six months ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack subject to Rule 16b-3
		Seff Leslie over six months ago Acquisition by Seff Leslie of 22727 shares of GlucoTrack at 1.98 subject to Rule 16b-3

GlucoTrack's Outstanding Corporate Bonds

GlucoTrack issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlucoTrack uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlucoTrack bonds can be classified according to their maturity, which is the date when GlucoTrack has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Boeing Co 2196 Corp Bond US097023DG73	View
	US45824TBC80 Corp Bond US45824TBC80	View
	MPLX LP 4125 Corp Bond US55336VAK61	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	International Game Technology Corp Bond US460599AD57	View
	IFCCN 5459 22 SEP 32 Corp Bond US45823TAL08	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	Morgan Stanley 3971 Corp Bond US61744YAL20	View

View All GlucoTrack Corporate Bonds

Understand GlucoTrack's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing GlucoTrack's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.0881
	Market Risk Adjusted Performance	0.2163
	Mean Deviation	4.69
	Semi Deviation	7.17
	Downside Deviation	8.79
	Coefficient Of Variation	973.74
	Standard Deviation	8.2
	Variance	67.27
	Information Ratio	0.0821
	Jensen Alpha	0.1912
	Total Risk Alpha	(0.86)
	Sortino Ratio	0.0766
	Treynor Ratio	0.2063
	Maximum Drawdown	63.42
	Value At Risk	(9.02)
	Potential Upside	13.79
	Downside Variance	77.2
	Semi Variance	51.34
	Expected Short fall	(5.20)
	Skewness	(0.22)
	Kurtosis	6.6

	Risk Adjusted Performance	0.0881
	Market Risk Adjusted Performance	0.2163
	Mean Deviation	4.69
	Semi Deviation	7.17
	Downside Deviation	8.79
	Coefficient Of Variation	973.74
	Standard Deviation	8.2
	Variance	67.27
	Information Ratio	0.0821
	Jensen Alpha	0.1912
	Total Risk Alpha	(0.86)
	Sortino Ratio	0.0766
	Treynor Ratio	0.2063
	Maximum Drawdown	63.42
	Value At Risk	(9.02)
	Potential Upside	13.79
	Downside Variance	77.2
	Semi Variance	51.34
	Expected Short fall	(5.20)
	Skewness	(0.22)
	Kurtosis	6.6

Consider GlucoTrack's intraday indicators

GlucoTrack intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GlucoTrack stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	16022.86
	Daily Balance Of Power	0.4324
	Rate Of Daily Change	1.11
	Day Median Price	1.61
	Day Typical Price	1.59
	Price Action Indicator	0.045
	Period Momentum Indicator	0.16
	Relative Strength Index	27.7

GlucoTrack time-series forecasting models is one of many GlucoTrack's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GlucoTrack's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

GlucoTrack Stock media impact

Far too much social signal, news, headlines, and media speculation about GlucoTrack that are available to investors today. That information is available publicly through GlucoTrack media outlets and privately through word of mouth or via GlucoTrack internal channels. However, regardless of the origin, that massive amount of GlucoTrack data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of GlucoTrack news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GlucoTrack relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GlucoTrack's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GlucoTrack alpha.

GlucoTrack Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards GlucoTrack can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

GlucoTrack Corporate Management

Erez BenZvi	GM Product	Profile
Drinda Benjamin	Vice Marketing	Profile
Paul Goode	Chief Officer	Profile
MScEE MBA	Chairman CoFounder	Profile
Mark Tapsak	Vice Technology	Profile
Esq CPA	Chief Officer	Profile
David BA	CoFounder	Profile

When determining whether GlucoTrack is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlucoTrack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glucotrack Stock. Highlighted below are key reports to facilitate an investment decision about Glucotrack Stock: